Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.44M
Average 0.33M
AKTS Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Aktis Oncology, Inc.NASDAQ: AKTS
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin of $5.25M in Q1 FY2026
Q1 FY2026 selling, general & admin was $5.25M. Over 3 fiscal years it compounded at +35.1% a year.
Context
- Selling, general & admin amounted to 193.9% of revenue in FY2025, down 566.5 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $42.95M (+240.9%) for the fiscal year ending Dec 2026, a step up from the +11.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $5.25M+109.0% QoQ
- Last fiscal yearDec 2025
- $12.6M+11.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | +11.4% | +240.9% | +229.5 pp |
| 3-year CAGR | +35.1% | +35.4% | +0.2 pp |
| 5-year CAGR | +85.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 12.6M USD
- Year-over-year change
- +11.4%
- 3-year CAGR
- +35.1%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.6M | +11.4% |
| FY2024 | 2024-12-31 | 11.31M | +47.2% |
| FY2023 | 2023-12-31 | 7.68M | +50.4% |
| FY2022 | 2022-12-31 | 5.11M | — |
Selling, General & Admin vs competitors
How AKTS compares with its peers on the latest reported figures
- AKTS's FY2025 selling, general & admin of $12.6M is the lowest of the 6 companies compared; the peer median is $64.15M.
- Its year-over-year change of +11.4% is the 2nd highest of 6, against a peer median of +0.6%.
- Selling, general & admin amounts to 193.9% of revenue for AKTS, versus a peer median of 39.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $151.41M | -3.4% | — | 39.2% | |
| LTM Mar 2026 | $76.67M | +0.6% | +17.4% | 120.8% | |
| LTM Sep 2026 | $64.15M | +52.3% | +47.5% | — | |
| LTM Mar 2026 | $38.15M | -27.9% | -12.7% | 24.3% | |
| LTM Mar 2026 | $23.71M | +3.3% | +7.6% | — | |
| FY2025 | $12.6M | +11.4% | +35.1% | 193.9% | |
| Peer median (excluding AKTS) | $64.15M | +0.6% | +12.5% | 39.2% | |
Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 1.49M | 6.5M |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 1.49M | 6.5M |
| Gross Margin | — | — | 100.0% | 100.0% |
| Research & Development | 14.3M | 25.92M | 40.95M | 67.45M |
| Selling, General & Admin | 5.11M | 7.68M | 11.31M | 12.6M |
| Operating Expenses | 19.76M | 34.79M | 53.54M | 81.18M |
| Depreciation & Amortization | 445K | 1.2M | 1.58M | 2.33M |
| EBITDA | (17.48M) | (27.45M) | (42.41M) | (61.4M) |
| EBITDA Margin | — | — | -2851.7% | -945.1% |
| Operating Income | (19.76M) | (34.79M) | (52.05M) | (74.68M) |
| Operating Margin | — | — | -3500.3% | -1149.5% |
| Interest Income | 1.65M | 5.38M | 8.1M | 11.01M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.84M | 6.15M | 8.07M | 10.95M |
| Income Before Tax | (17.93M) | (28.64M) | (43.98M) | (63.73M) |
| Pre-Tax Margin | — | — | -2957.6% | -980.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (17.93M) | (28.64M) | (43.98M) | (63.73M) |
| Net Margin | — | — | -2957.6% | -980.9% |
| EPS (Basic) | (0.51) | (0.82) | (1.26) | (1.19) |
| EPS (Diluted) | (0.51) | (0.82) | (1.26) | (1.19) |
| Weighted Avg Shares | 34.86M | 34.86M | 34.86M | 52.52M |
| Weighted Avg Shares (Diluted) | 34.86M | 34.86M | 34.86M | 52.52M |
Aktis Oncology, Inc.
NASDAQ:AKTS
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.